Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (3437)	12/27/1997 1:00:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

If I sell ALL my AGPH Monday ($30,000+ loss), how much of a tax write-off can I take? I guess, like a dummy investor, I should have sold at 50+ ($30,000+ profit) and bought back at <$30.

To: billkirn who wrote (3437)	12/30/1997 12:32:00 AM
From: BriBear	Read Replies (1) \| Respond to of 6136

Re: "Lilly recently pulled their GART inhibitor off trials..." Based on what I found on the FDA's web-site (link below) Phase 1 trials are "mainly safety", while Phase 2 trials are "Some short-term safety but mainly effectiveness". If AG2043 has made it OK thru Phase 1 and really will go into Phase 2 in '98, no sweat (at least, for acute toxicity; effectiveness is another matter). I haven't been able to find anything authoritative about what phase Lilly's GART inhibitor was in - does anyone know? Also, any news about Phase 1 results for AG2043? Bill, can you find out from AGPH IR if AG2043 is even in the same class of compunds as the Lilly drug? fda.gov Bright*Blessings to all in the New Year